相关实验视频

Updated: May 27, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

在COVID-19的糖尿病实验模型中,西塔利普丁的发病和治疗效果

Qinghe Meng¹, Ikechukwu Jacob¹, Chunyan Wang¹

¹Departments of Surgery and Pathology, Microbiology and Immunology, State University of New York (SUNY), Upstate Medical University, Syracuse, New York, USA.

Biochimica et biophysica acta. Molecular basis of disease

|February 19, 2025

概括

西塔格利普丁通过减少器官损伤,炎症和改善葡萄糖控制,有效地治疗糖尿病小鼠的严重COVID-19. 这项研究强调了西塔格利普丁的作用.

科学领域:

病毒学和免疫学病毒学和免疫学
代谢疾病代谢疾病
药理学药理学是指药理学的学科.

背景情况:

COVID-19 (2019年冠状病毒疾病) 会加剧已经存在的疾病,如糖尿病.
糖尿病患者面临较高的风险和死亡率来自SARS-CoV-2 (严重急性呼吸系统综合征冠状病毒2) 感染.
了解SARS-CoV-2病原和糖尿病之间的相互作用对于开发有效的治疗方法至关重要.

研究的目的:

在糖尿病小鼠模型中评估COVID-19的发病性.
评估在糖尿病小鼠中减轻COVID-19严重性的西塔利普丁的治疗疗效.
调查HaaCE2,NF-κB和IRS-1在SARS-CoV-2引起的糖尿病和西塔格利普丁的作用中的机制性作用.

主要方法:

使用了一种新的双转基因小鼠模型 (db/db和K18-hACE2) 感染SARS-CoV-2 (三角洲变种).
感染糖尿病小鼠与非糖尿病对照小鼠的结局比较.
服用西塔利普丁,以评估其对器官损伤,炎症,葡萄糖代谢和激素水平的影响.

主要成果:

在糖尿病小鼠中,SARS-CoV-2感染导致严重的多器官损伤,高血糖症,胰岛素耐药性和胰腺小岛细胞损伤.
受感染的糖尿病小鼠表现出增加的死亡率,炎症 (TNF-α,IL-6,IL-1β) 和纤维解质活性 (PAI-1).
西塔格利普丁治疗显著降低了器官损伤,高血糖症,炎症和纤维溶解活性,同时改善了胰岛素抵抗,葡萄糖代谢,胰岛素和GLP-1水平.

结论:

西塔格利普丁在糖尿病患者的严重COVID-19治疗中显示出有前途的治疗潜力.
该药物有效调节炎症并改善代谢综合征,提供减轻疾病严重程度的策略.
hACE2表达,NF-κB和IRS-1激活是SARS-CoV-2引起的糖尿病恶化和西塔格利普丁治疗效果的关键因素.

关键词:

在 COVID-19 疫情中,糖尿病糖尿病糖尿病葡萄糖耐受性是一种耐受性.炎症炎症是一种炎症.胰岛素耐药性胰岛素耐药性是一种肥胖问题肥胖问题这就是SARS-CoV-2病毒.西塔格利普丁是如何使用的

更多相关视频

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Pathophysiology of Diabetes

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Overview of Carbohydrate Metabolism

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...